20-F: BioLineRx Refocuses on Oncology, Rare Diseases Amidst Going Concern Warning

BioLineRx Ltd. shifts strategic focus to oncology and rare diseases after out-licensing its approved drug APHEXDA, despite ongoing significant losses and a 'going concern' warning from management.

Summary

• BioLineRx has refocused its operations on development activities in Israel in oncology and rare diseases, significantly reducing its annual cash burn rate.
• The company out-licensed global rights (excluding Asia) for APHEXDA (motixafortide) for all indications other than solid tumors to Ayrmid Pharma Ltd. in November 2024, receiving a $10 million upfront payment and eligibility for up to $87 million in commercial/sales milestones and tiered double-digit royalties (18-23%).
• Rights to motixafortide in Asia were out-licensed to Gloria in October 2023, with a $15 million upfront payment, up to $49 million in development/regulatory milestones, and up to $197 million in sales milestones, plus tiered double-digit royalties (10-20%).
• A collaboration with Hemispherian AS was established in September 2025 for GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma (GBM) and other cancers, with BioLineRx holding 40% of the newly formed Tetragon Biosciences Ltd. and committing to invest $5 million over 36 months.
• The company reported net losses of $60.6 million in 2023, $9.2 million in 2024, and $2.0 million in 2025, with an accumulated deficit of $401 million as of December 31, 2025.
• Cash, cash equivalents, and short-term bank deposits totaled $20.9 million as of December 31, 2025, with management believing these funds are sufficient into the first half of 2027.
• Net cash used in operating activities decreased significantly to $8.1 million in 2025 from $43.9 million in 2024 due to reduced operating expenses post-Ayrmid transaction.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern, a sentiment echoed by its independent registered public accounting firm.
• Sales and marketing expenses were eliminated in 2025, down from $23.6 million in 2024, following the shutdown of U.S. commercial operations.
• Research and development expenses decreased by 11.5% to $8.1 million in 2025, primarily due to lower motixafortide expenses and reduced headcount, partially offset by GLIX1 project initiation costs.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' warning, significant accumulated losses, and ongoing negative cash flows, which overshadow positive developments like new collaborations and reduced burn rate. The delay in a key clinical study further adds to the uncertainty.

Positives

• FDA approval of APHEXDA (motixafortide) in September 2023 for stem cell mobilization in multiple myeloma patients.
• Successful out-licensing of APHEXDA rights to Ayrmid Pharma Ltd. (globally, excluding Asia) and Gloria (in Asia), generating upfront payments and potential future milestones and royalties.
• New collaboration with Hemispherian AS for GLIX1, a promising first-in-class oncology drug candidate with Orphan Drug Designation from FDA and EMA for GBM.
• Significant reduction in annual cash burn rate and elimination of sales and marketing expenses following the shutdown of U.S. commercial operations.
• Positive preliminary data from the investigator-initiated Phase 2 combination trial of motixafortide in first-line pancreatic cancer, showing a 64% partial response rate and 91% disease control rate in the pilot phase.
• Successful completion of a Phase 1 clinical trial evaluating motixafortide for gene therapies in Sickle Cell Disease, demonstrating safety and robust HSC mobilization.
• Arbitrator issued a final award in the company's favor, denying all claims in the Biokine lawsuit and awarding the company expenses.

Negatives

• Incurred significant losses since inception, with an accumulated deficit of $401 million as of December 31, 2025.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern, a concern highlighted by the independent auditor.
• The planned Phase 2b randomized study of motixafortide in first-line pancreatic cancer in China under the Gloria License Agreement is currently delayed, with an unclear initiation timeline.
• The company has earned only limited revenues to date and may never achieve profitability, relying heavily on licensee efforts for future revenue.
• Reliance on third-party manufacturers and contract research organizations introduces risks of unsatisfactory performance, delays, or increased costs.
• The company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, potentially leading to negative tax consequences for U.S. investors.

Risks

• Incurred significant losses since inception and expects additional losses, with no assurance of future profitability.
• Existing cash and investment balances may be insufficient to meet future capital requirements, necessitating additional financing which may not be available on reasonable terms or at all.
• Default under the secured loan agreement with BlackRock could lead to forfeiture of assets.
• GLIX1, motixafortide, or any future therapeutic candidate may fail to achieve sufficient market acceptance.
• Inability to obtain and/or maintain U.S. and/or foreign regulatory approval for therapeutic candidates in a timely manner or at all.
• Clinical trials are lengthy, expensive, and have uncertain outcomes, with earlier results not predictive of future success.
• Approved products are subject to ongoing regulatory review, and failure to comply with regulations could lead to loss of approvals.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing may lead to unsatisfactory performance or missed deadlines.
• Dependence on out-licensing and collaboration arrangements subjects the company to risks of limited control, financial difficulties of partners, and potential termination of agreements.
• Failure to meet requirements under in-license and collaboration agreements could result in loss of rights to therapeutic candidates.
• Competition from more effective, safer, or less expensive therapies could negatively impact prospects.
• Therapeutic candidates may become subject to unfavorable pricing regulations, third-party payor reimbursement practices, or healthcare reform initiatives.
• Significant disruptions of information technology systems or data security breaches could adversely affect business.
• Operations in Israel are subject to political, geopolitical, economic, and military instability, which could harm results.
• Provisions of Israeli law may delay, prevent, or impede mergers or acquisitions.
• Difficulty in enforcing U.S. judgments against the company and its officers/directors in Israel or the U.S.

Future Outlook

The company aims to continue advancing GLIX1 and motixafortide in solid tumor indications, and to pursue additional in-licensing opportunities and strategic transactions in oncology and rare diseases. The longer-term vision is to develop innovative assets with significant potential value, with development costs offset by royalties and milestones from existing motixafortide partnerships. Management believes existing cash and investment balances will fund operations into the first half of 2027, but acknowledges the need for additional funding through various sources.

Management Comments

• Management believes that existing cash and investment balances will be sufficient to meet capital requirements into the first half of 2027.
• Management monitors rolling forecasts of liquidity reserves based on anticipated cash flows and seeks to maintain sufficient liquidity.
• Management's plans include the realization of capital inflows from strategic partnerships and, if required, raising capital through debt or equity securities.

Industry Context

StockSavvy.ai notes that BioLineRx operates in a highly competitive and cost-sensitive biopharmaceutical industry. The focus on oncology and rare diseases aligns with industry trends seeking high-value, unmet medical needs. The entry of generic versions of Mozobil (plerixafor) underscores the intense competition in stem cell mobilization, requiring strong differentiation for APHEXDA. The high attrition rate in pancreatic cancer development, as noted by multiple clinical failures, highlights the significant challenges GLIX1 faces, despite its novel mechanism. The increasing scrutiny on pharmaceutical pricing and reimbursement, particularly from government programs like Medicare, poses a continuous headwind for commercial success.

Comparison to Industry Standards

• In glioblastoma (GBM), GLIX1 competes with established modalities like temozolomide chemotherapy and Novocure's Optune device. For recurrent GBM, Bevacizumab (Avastin) and GLIADEL wafer are approved. Other agents in late-stage development include radiotherapeutics Reyobiq (Plus Therapeutics) and TLX-101 (Telix), cancer vaccines TVI-Brain-1 (TVAX Biomedical) and IGV-001 (Imvax), and GSK's PARP inhibitor niraparib.
• In stem cell mobilization, motixafortide directly competes with Mozobil (plerixafor) and its recently launched generic versions from companies like Dr. Reddy's Laboratories Ltd., Teva Pharmaceuticals USA, Inc., and MSN Laboratories Private Ltd. Exicure's burixafor is also under clinical investigation.
• In pancreatic cancer, motixafortide competes indirectly with current first-line standards of care such as gemcitabine in combination with Abraxane or the FOLFIRINOX regimen. Ipsen's Onivyde, LYNPARZA, and BIZENGRI are approved for second-line or specific biomarker-driven cases. Late clinical-stage developments include daraxonrasib (Revolution Medicines) and quemliclustat (Arcus Biosciences), alongside Chinese antibody modalities. The industry has seen multiple clinical failures in advanced PDAC, including FibroGen's pamrevlumab, Erytech's eryaspase, and Astellas' zolbetuximab, indicating the difficulty of success in this area.

Management Changes

Corporate Governance

Legal Proceedings

• Biokine Therapeutics Ltd. filed a complaint in June 2024 alleging breach of contract and failure to make payments under the motixafortide in-licensing agreement, seeking approximately $7.2 million in damages. The dispute was referred to binding arbitration in November 2024. In February 2026, the arbitrator issued a final award in the company's favor, denying all claims and awarding the company expenses, including legal fees.

Related Party Transactions

• **Gloria License Agreement and Securities Purchase Agreement:** In August 2023, the company entered into a license agreement with Hong Seng Technology Limited (HST) and Gloria, granting exclusive rights to motixafortide in Asia. Concurrently, the company sold 170,728 ADSs to HST and Gloria in a private placement for approximately $14.6 million. Dr. Shaoyu Yan, a nominee of HST, was appointed to the board of directors.
• **Ayrmid License Agreement and Highbridge Capital Management LLC:** In November 2024, the company entered into a license agreement with Ayrmid Pharma Ltd. (a related party to Highbridge Capital Management LLC) for motixafortide rights globally (excluding Asia and solid tumors). Concurrent with this, the company completed a registered direct offering with certain funds associated with Highbridge, raising $9.0 million in gross proceeds through ADSs and pre-funded warrants.

Stakeholder Impact

• **Shareholders:** Face significant risk due to the 'going concern' warning and accumulated losses, potentially leading to substantial losses on their investment. Future capital raises could dilute existing ownership. However, successful pipeline development and milestone payments could provide value.
• **Employees:** The company undertook cost-cutting and workforce reduction measures following the Ayrmid License Agreement, reducing the number of full-time employees to 20 and part-time to 4, indicating job insecurity for some.
• **Customers (Patients):** Potential for life-changing therapies in oncology and rare diseases (APHEXDA, GLIX1, motixafortide in PDAC) could offer new treatment options.
• **Licensors (Biokine, IPC, Hemispherian):** Future milestone and royalty payments depend on the commercial success and continued development of licensed products by BioLineRx and its licensees. Failure to meet obligations could lead to loss of rights for BioLineRx.
• **Creditors (BlackRock):** The company's ability to make scheduled loan payments depends on cash reserves and future financing. Default could result in BlackRock taking possession of secured assets.

Next Steps

• Initiate Phase 1/2a study for GLIX1 in GBM and other cancers in Q1 2026.
• Conduct interim futility analysis for the Phase 2b randomized study in first-line pancreatic cancer in 2026.
• Expect data from the St. Jude Children's Research Hospital Phase 1 study for gene therapies in SCD in 2026.
• Achieve full enrollment for the Phase 2b randomized study in first-line pancreatic cancer by 2027.
• Receive Phase 1 data for GLIX1 in H1 2027.
• Receive Phase 2 data for GLIX1 in H1 2028.
• Continue to explore alternative financing sources, including future securities offerings and government funding.

Key Dates

Recommendation

The company's explicit 'substantial doubt about our ability to continue as a going concern,' coupled with a significant accumulated deficit of $401 million and ongoing losses, presents an extremely high level of financial risk. While strategic out-licensing and new collaborations offer long-term potential, the immediate financial instability and reliance on future capital raises make the stock highly speculative. A seasoned investor would prioritize capital preservation and avoid companies with such fundamental solvency concerns, regardless of pipeline developments.

Keywords

Oncology, Rare Diseases, Biopharmaceutical, APHEXDA, Motixafortide, GLIX1, Glioblastoma, Pancreatic Cancer, Stem Cell Mobilization, Drug Development, Clinical Trials, SEC Filing, 20-F, Biotech, Pharmaceutical, Licensing, Collaboration, Going Concern, Financial Results